Review Evaluates Pharmacologic Treatments for Female Sexual Dysfunction, Including New Options
Background
Many women experience female sexual dysfunction (FSD), with hypoactive sexual desire disorder (HSDD) being a prevalent subtype characterized by a persistent lack of sexual thoughts or desire, causing personal distress. Despite its impact, effective and widely adopted pharmacologic treatments remain limited. This review addresses the critical need for comprehensive clinical guidance on current and emerging pharmacologic options for FSD, particularly HSDD.
Results
The review highlighted that flibanserin, a serotonin 1A receptor agonist, has shown modest efficacy in increasing satisfying sexual events in premenopausal women with HSDD. Bremelanotide, an alpha-melanocyte stimulating hormone (alpha-MSH) receptor agonist, offers an on-demand treatment option, demonstrating significant improvements in sexual desire and distress. Investigational therapies like Lorexys (a combination of bupropion and naltrexone) and various testosterone combinations are also showing promise, targeting different neurochemical pathways involved in sexual desire. The review underscores the importance of personalized treatment approaches, considering both two FDA-approved and multiple emerging options to address the multifaceted nature of female sexual dysfunction effectively. These treatments collectively offer a range of mechanisms, from modulating neurotransmitters to hormonal regulation, providing clinicians with a broader toolkit for patient care.
Why It Matters
This comprehensive review is crucial for advancing clinical practice in managing female sexual dysfunction, a condition affecting a significant number of women. By consolidating information on both established and novel pharmacologic agents, it equips healthcare providers with the knowledge to make informed treatment decisions. The insights provided could accelerate the adoption of effective therapies, significantly improving the quality of life for women suffering from HSDD. Future research should focus on comparative effectiveness studies and further development of investigational compounds, potentially leading to Phase II and III human trials for emerging treatments.